Advanced Search
Article Contents
ABOUT THIS ARTICLE
The Innovation Medicine > 2024 Vol. 2 > No. 3 > 100084
Next Article Previous Article
COMMENTARY   Open Access     Cite

Targeting early EBV-driven IDO1-NAD metabolism as a potential therapeutic strategy for EBV-related diseases

  • 1.

    Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China

  • 2.

    School of Medicine, Shanghai University, Shanghai 200444, China

  • 3.

    State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Xi'an 710032, Ganzhou 341000, China

  • 4.

    Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China

  • 5.

    These authors contributed equally

More Information
The Innovation Medicine  2(3),  https://doi.org/10.59717/j.xinn-med.2024.100084  |  Cite this article
    • FullText(HTML)
  • 加载中
    • REFERENCES
  • [1] Lv, M., Shen, M., and Mo, X. (2023). Development of allogeneic hematopoietic stem cell transplantation in 2022: Regenerating “Groot” to heal the world. The Innovation 4: 100373. DOI: 10.1016/j.xinn.2023.100373.

    View in Article CrossRef Google Scholar Scopus

    [2] Choi, I.K., Wang, Z., Ke, Q., et al. (2021). Mechanism of EBV inducing anti-tumour immunity and its therapeutic use. Nature 590: 157−162. DOI: 10.1038/s41586-020-03075-w.

    View in Article CrossRef Google Scholar Scopus

    [3] McFadden, K., Hafez, A.Y., Kishton, R., et al. (2016). Metabolic stress is a barrier to Epstein–Barr virus-mediated B-cell immortalization. Proc. Natl. Acad. Sci. U. S. A. 113: E782−790. DOI: 10.1073/pnas.1517141113.

    View in Article CrossRef Google Scholar

    [4] Bonglack, E.N., Messinger, J.E., Cable, J.M., et al. (2021). Monocarboxylate transporter antagonism reveals metabolic vulnerabilities of viral-driven lymphomas. Proc. Natl. Acad. Sci. U. S. A. 118: e2022495118. DOI: 10.1073/pnas.2022495118.

    View in Article CrossRef Google Scholar Scopus

    [5] Müller-Durovic, B., Jäger, J., Engelmann, C., et al. (2024). A metabolic dependency of EBV can be targeted to hinder B cell transformation. Science 385: eadk4898. DOI: 10.1126/science.adk4898.

    View in Article CrossRef Google Scholar Scopus

    • Cited by

  • Cite this article:

    Luo L., Pei X., Zhang C., et al., (2024). Targeting early EBV-driven IDO1-NAD metabolism as a potential therapeutic strategy for EBV-related diseases. The Innovation Medicine 2(3): 100084. https://doi.org/10.59717/j.xinn-med.2024.100084
    Luo L., Pei X., Zhang C., et al., (2024). Targeting early EBV-driven IDO1-NAD metabolism as a potential therapeutic strategy for EBV-related diseases. The Innovation Medicine 2(3): 100084. https://doi.org/10.59717/j.xinn-med.2024.100084

Welcome!

To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.

PDF
Figures(1)    

Share

  • Share the QR code with wechat scanning code to friends and circle of friends.

Article Metrics

Article views(4686) PDF downloads(1632)

Relative Articles

Cited by

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return

    {{newsColumn.name}}

    {{newsColumn.name}}

    Stay connected

    {{newsColumn.name}}

    Website copyright © Innovation Press. Published articles are licensed under CC BY with copyright retained by the authors.